

## Subscription period for Vimian's incentive program 2022-2025 has commenced

**Vimian Group AB (publ) ("Vimian") announces that the subscription period for Vimian's incentive program 2022-2025, a warrant program for employees in the group ("LTI 2022") commenced on 15 June 2025 in accordance with the terms and conditions of LTI 2022. Each warrant under LTI 2022 entitles the holder to subscribe for 1.025734 ordinary shares (after recalculation following the rights issue carried out in 2024) in Vimian at an exercise price of SEK 37.92. The subscription period ends on 30 June 2025.**

To finance the share subscription, a number of warrant holders have chosen to sell a total of 2,420,013 ordinary shares. The sale of the shareholding was carried out on the market by DNB Carnegie Investment Bank. To facilitate the transaction, Vimian's largest shareholder, Fidelio Vet Holding AB ("**Fidelio**"), lent ordinary shares in Vimian to DNB Carnegie Investment Bank, which has undertaken to return these shares without delay as soon as practicable after the share subscription has been registered with the Swedish Companies Registration Office.

To facilitate the process for foreign warrant holders, Fidelio has further acquired a total of 253,577 warrants from the foreign warrant holders, which will be exercised to subscribe for ordinary shares. Fidelio has simultaneously sold the corresponding number of ordinary shares on the market through DNB Carnegie to create liquidity for the warrant holders. Following the transactions, Fidelio will retain the same shareholding as before.

**For further information, please contact:**

---

### **Maria Dahllöf Tullberg**

Head of IR, Communications & Sustainability

[maria.tullberg@vimian.com](mailto:maria.tullberg@vimian.com)

+46 73 626 88 86

### **About Vimian**

---

Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Veterinary Services and Diagnostics. At Vimian, we believe that every animal deserves the best available care. We bring pioneering and entrepreneurial businesses together to make the market's most innovative offerings accessible to more animal health professionals and pet owners. Headquartered in Stockholm, Sweden, Vimian reaches over 17,000 veterinary clinics and laboratories, sells to over 80 markets, has 1,200 employees and annual revenues of approximately EUR 375 million. For more information, please visit: [www.vimian.com](http://www.vimian.com).

Press Release  
17 June 2025 17:30:00 CEST

---

## Attachments

---

[Subscription period for Vimian's incentive program 2022-2025 has commenced](#)